(Source: Business Wire)
pSivida Corp, (NASDAQ:PSDV)(ASX:PSD)(FF:PSI), a leading drug delivery
company, today announced that Dr. Paul Ashton, CEO, will lead a
discussion on New Technologies in Retinal Drug Delivery at the 5th
Annual Ophthalmic Drug Development and Delivery Summit to be held
September 21-22, 2009 in San Diego.
Dr. Ashton will describe the anatomical and technical difficulties of
drug delivery to the retina; the advantages and disadvantages of earlier
approaches to overcome these obstacles; current attempts to achieve
effective dosing to the retina and provide an outlook on future
developments in retinal delivery.
More information on the Summit can be found at its website: http://www.pharmedassociates.com.
About pSivida Corp.
pSivida is a world leader in the development of miniaturized,
injectable, drug delivery systems for the eye. pSivida's lead
development product, Iluvien, delivers fluocinolone acetonide (FA) for
the treatment of diabetic macular edema (DME). Formerly known as
Medidur FA for DME, Iluvien is in fully recruited Phase III clinical
trials. pSivida has licensed certain drug delivery technology to Alimera
Sciences, Inc. for the development of Iluvien and certain other
ophthalmic products. pSivida also has two products approved by the Food
and Drug Administration (FDA): Retisert® for the treatment of
uveitis and Vitrasert® for the treatment of AIDS-related
cytomegalovirus (CMV) retinitis. pSivida has licensed both of these
products and the technologies underlying them to Bausch & Lomb
Incorporated. pSivida has a worldwide collaborative research and license
agreement with Pfizer Inc. under which Pfizer may develop additional
ophthalmic products.
pSivida owns the rights to develop and commercialize a modified form of
silicon known as BioSilicon, which has potential therapeutic
applications. The most advanced BioSilicon product candidate,
BrachySil, delivers a therapeutic P32, a radioactive form of phosphorus
used to treat cancer, directly to solid tumors. pSivida has completed an
initial safety clinical trial of BrachySil for the treatment of
pancreatic cancer and is conducting a follow-on dose-ranging clinical
trial.
pSivida's intellectual property portfolio consists of 45 patent
families, over 100 granted patents, including patents accepted for
issuance, and over 200 patent applications. pSivida conducts its
operations from Boston in the United States and Malvern in the United
Kingdom.
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995: Various statements made in this release are forward-looking
and involve a number of risks and uncertainties.
